Temodar Related Published Studies
Well-designed clinical trials related to Temodar (Temozolomide)
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. [2011.09.20]
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. [2011.07]
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. [2011.06.07]
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. [2010.11]
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. [2010.10.20]
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. [2010.05]
Evaluation of the exposure equivalence of oral versus intravenous temozolomide. [2010.03]
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. [2010.02]
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. [2010.01]
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. [2009.12.10]
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. [2009.08.10]
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma] [2009.08.04]
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. [2009.05]
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. [2009.04.21]
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. [2009.03.10]
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. [2007.06.20]
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. [2006.09]
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. [2006.06.01]
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. [2005.12.10]
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. [2005.06]
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. [2005.04.01]
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. [2005.03.10]
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. [2005.01.01]
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. [2004.08]
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. [2004.07]
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. [2004.03.01]
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. [2003.07.01]
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. [2003]
Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. [2002.09.01]
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. [2002.04]
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. [2002.02.12]
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. [2000.09]
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. [2000.04]
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. [2000.04]
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. [2000.01]
Well-designed clinical trials possibly related to Temodar (Temozolomide)
New treatment strategies in advanced neuroendocrine tumours. [2011.10.07]
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. [2011.06]
Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. [2011.03]
Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. [2011.01]
Postoperative chemo-radiotherapy with temodal in patients with glioblastoma multiforme--survival rates and prognostic factors. [2010.01]
The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. [2010.01]
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. [2009.12.10]
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. [2009.11.15]
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. [2009.06.10]
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. [2008.06.20]
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. [2008.02.20]
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. [2008.01]
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. [2007.06.01]
Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. [2007.01]
PRIMARY AND METASTATIC BRAIN TUMORS. [2006.06.01]
Health-related quality of life in patients with glioblastoma: a randomised controlled trial. [2005.12]
State-of-the-art treatment of high-grade brain tumors. [2003.12]
Other research related to Temodar (Temozolomide)
Going past the data for temozolomide. [2012]
Outcome, quality of life and cognitive function of patients with brain metastases
from non-small cell lung cancer treated with whole brain radiotherapy combined
with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group
for Clinical Cancer Research (SAKK 70/03). [2012]
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as
monotherapy versus temozolomide in patients with advanced melanoma. [2012]
Going past the data for temozolomide. [2011.12.07]
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. [2011.12]
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). [2011.11.15]
Phase II Study of Short-Course Radiotherapy plus Concomitant and Adjuvant Temozolomide in Elderly Patients with Glioblastoma. [2011.11.11]
Temozolomide plus radiotherapy for glioblastoma in a Canadian province: Efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation. [2011.11.07]
Phase II, Open-Label, Randomized Trial of the MEK 1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. [2011.11.02]
Glioblastoma survival in the United States before and during the temozolomide era. [2011.11.02]
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. [2011.11]
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. [2011.11]
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. [2011.10.28]
Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. [2011.09.21]
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O-methylguanine-DNA methyltransferase and mismatch repair proteins. [2011.09.01]
Gene expression profiles predicting the response to IFN-beta and a combination of temozolomide and IFN-beta in malignant gliomas. [2011.09]
Adjuvant temozolomide chemotherapy for treatment of papillary tumor of the pineal region. [2011.07]
Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. [2011.04]
Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors. [2011]
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial
for glioblastoma. [2011]
Central nervous system failure in melanoma patients: results of a randomised,
multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. [2011]
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV
melanoma: final results of a randomised phase III study (EORTC 18032). [2011]
The sequential use of carmustine wafers (Gliadel®) and post-operative
radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a
clinical review. [2011]
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant
ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized
controlled multicenter phase III trial. [2011]
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. [2010.09.24]
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma. [2010.09.20]
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. [2010.09.18]
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. [2010.09.16]
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. [2010.09.07]
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. [2010.09.07]
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. [2010.09.06]
Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. [2010.09]
Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. [2010.09]
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. [2010.08.20]
Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. [2010.08.10]
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. [2010.08.01]
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. [2010.08]
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. [2010.08]
Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. [2010.07.21]
Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. [2010.06.15]
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. [2010.06.15]
A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide. [2010.03]
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent
high-grade glioma. [2010]
A phase I factorial design study of dose-dense temozolomide alone and in
combination with thalidomide, isotretinoin, and/or celecoxib as
postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. [2010]
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of
brain metastases from non-small-cell lung cancer: a randomized, open-label phase
II study. [2010]
Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomised phase III
study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466). [2010]
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant
temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly
diagnosed glioblastoma. [2010]
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. [2009.12]
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. [2009.10]
|
